JP2018062532A5 - - Google Patents

Download PDF

Info

Publication number
JP2018062532A5
JP2018062532A5 JP2018010718A JP2018010718A JP2018062532A5 JP 2018062532 A5 JP2018062532 A5 JP 2018062532A5 JP 2018010718 A JP2018010718 A JP 2018010718A JP 2018010718 A JP2018010718 A JP 2018010718A JP 2018062532 A5 JP2018062532 A5 JP 2018062532A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administration
specific promoter
cell type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018010718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018062532A (ja
JP6440875B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018062532A publication Critical patent/JP2018062532A/ja
Publication of JP2018062532A5 publication Critical patent/JP2018062532A5/ja
Application granted granted Critical
Publication of JP6440875B2 publication Critical patent/JP6440875B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018010718A 2013-10-29 2018-01-25 酸化ストレスを阻害するための方法および組成物 Active JP6440875B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361896805P 2013-10-29 2013-10-29
US61/896,805 2013-10-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016526853A Division JP6317440B2 (ja) 2013-10-29 2014-10-29 酸化ストレスを阻害するための方法および組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018217337A Division JP2019048858A (ja) 2013-10-29 2018-11-20 酸化ストレスを阻害するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2018062532A JP2018062532A (ja) 2018-04-19
JP2018062532A5 true JP2018062532A5 (cg-RX-API-DMAC10.html) 2018-06-07
JP6440875B2 JP6440875B2 (ja) 2018-12-19

Family

ID=53005074

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016526853A Active JP6317440B2 (ja) 2013-10-29 2014-10-29 酸化ストレスを阻害するための方法および組成物
JP2018010718A Active JP6440875B2 (ja) 2013-10-29 2018-01-25 酸化ストレスを阻害するための方法および組成物
JP2018217337A Pending JP2019048858A (ja) 2013-10-29 2018-11-20 酸化ストレスを阻害するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016526853A Active JP6317440B2 (ja) 2013-10-29 2014-10-29 酸化ストレスを阻害するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018217337A Pending JP2019048858A (ja) 2013-10-29 2018-11-20 酸化ストレスを阻害するための方法および組成物

Country Status (4)

Country Link
US (3) US10980896B2 (cg-RX-API-DMAC10.html)
EP (3) EP3062884B1 (cg-RX-API-DMAC10.html)
JP (3) JP6317440B2 (cg-RX-API-DMAC10.html)
WO (1) WO2015066190A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
RU2651757C2 (ru) * 2016-01-19 2018-04-23 Селл энд Джин Терапи Лтд Линейка биологически активных генно-терапевтических субстанций на основе гена sod2 для коррекции патологических состояний клеток органов и тканей и органов и тканей человека, связанных с оксидативным стрессом, способ получения и использования
RU2651758C2 (ru) * 2016-01-20 2018-04-23 Селл энд Джин Терапи Лтд Средство для коррекции патологических состояний клеток органов и тканей и/или органов и тканей человека, на основе гена gpx3, связанных с оксидативным стрессом, способ получения и использования
RU2653491C2 (ru) * 2016-01-20 2018-05-08 Селл энд Джин Терапи Лтд Линейка биологически активных генно-терапевтических субстанций на основе гена gpx1 для коррекции патологических состояний клеток органов и тканей и органов и тканей человека, связанных с оксидативным стрессом, способ получения и использования
RU2649820C2 (ru) * 2016-01-20 2018-04-04 Селл энд Джин Терапи Лтд Средство для коррекции патологических состояний клеток органов и тканей и/или органов и тканей человека на основе гена col1a2, связанных с количественным снижением белка альфа-2 цепи коллагена i типа
WO2017136805A1 (en) * 2016-02-06 2017-08-10 Georgetown University Compositions and methods for the diagnosis and treatment of age-related macular degeneration
RU2651048C1 (ru) * 2016-11-21 2018-04-18 Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена il-11 и/или уменьшением количества белка интерлейкина-11 на основе генно-терапевтических субстанций с геном il-11, способ получения и использования
RU2653487C1 (ru) * 2016-11-30 2018-05-08 Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена lif и/или уменьшением количества белка фактора, ингибирующего лейкемию, на основе генно-терапевтических субстанций с геном lif, способ получения и использования
RU2649814C1 (ru) * 2017-02-14 2018-04-04 Общество с ограниченной ответственностью "Медсервис" Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена сат и/или уменьшением активности белка каталазы на основе генно-терапевтических субстанций с геном сат, способ получения и использования
JP7105532B2 (ja) * 2017-05-10 2022-07-25 ロート製薬株式会社 後眼部疾患の予防、改善、又は治療用組成物
DK3684423T5 (da) 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
US20210381002A1 (en) * 2018-04-03 2021-12-09 Cornell University Gene therapy for oxidative stress
JOP20210030A1 (ar) 2018-08-20 2021-02-16 Janssen Pharmaceutica Nv مثبطات تفاعل البروتين-بروتين KEAP1-Nrf2
CN109055428A (zh) * 2018-09-19 2018-12-21 上海市第人民医院 一种重组腺相关病毒载体及其制备方法与应用
WO2020132040A1 (en) * 2018-12-20 2020-06-25 President And Fellows Of Harvard College Compositions and methods for the treatment of degenerative ocular diseases
WO2020167770A1 (en) * 2019-02-11 2020-08-20 President And Fellows Of Harvard College Txnip and ldhb compositions and methods for the treatment of degenerative ocular diseases
CA3175905A1 (en) 2020-04-27 2021-11-04 David H. Kirn Codon optimized gla genes and uses thereof
CA3177580A1 (en) * 2020-05-04 2021-11-11 Sulfagenix, Inc. Treatment of viral infections
JP2023528661A (ja) * 2020-06-09 2023-07-05 ジェネトン 拡張型心筋症の処置における使用のためのｎｒｆ２活性化剤
KR102620997B1 (ko) * 2022-11-10 2024-01-04 주식회사 아이두젠 노각나무 추출물을 유효성분으로 포함하는 시력 보호용 또는 망막 질환의 개선 및 예방용 조성물
WO2025110266A1 (ko) * 2023-11-21 2025-05-30 주식회사 퓨어바이오 시력 보호 또는 망막 질환의 개선, 예방 또는 치료를 위한 노각나무 추출물의 용도

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4598049A (en) 1983-08-31 1986-07-01 Systec Inc. General purpose gene synthesizer
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US5591624A (en) 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
CA1336396C (en) 1988-07-25 1995-07-25 Kiyoshi Kita Intraocular anticoagulant including antithrombin iii and method of administration
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5756096A (en) 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
WO1995006486A1 (en) 1993-09-03 1995-03-09 Government Of The United States Of America, Secretary Department Of Health And Human Services Treatment of human tumors by genetic transformation of human tumor cells
US5763217A (en) 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5763242A (en) 1995-02-08 1998-06-09 Thomas Jefferson University Method for increasing transduction efficiency of recombinant retroviral vectors
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5994132A (en) 1996-10-23 1999-11-30 University Of Michigan Adenovirus vectors
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
EP1162887A4 (en) 1999-03-15 2003-06-25 John Guy GENE TRANSFER BY RECOMBINANT ADENO-ASSOCIATED VIRUS INFLUENCING DEMYELINIZATION
US20020049176A1 (en) * 1999-11-10 2002-04-25 Anderson Christen M. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
US20080274093A1 (en) * 2004-12-02 2008-11-06 Johnson Jeffrey A Method of diminishing the symptoms of neurodegenerative disease
AU2006265113A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
EP2089412A4 (en) 2006-10-23 2010-01-27 John Guy SUPPRESSION OF OXIDATIVE STRESS OF MITOCHONDRIEN
EP2653873B8 (en) 2007-02-08 2022-08-24 Biogen MA Inc. Compositions and uses for treating Multiple Sclerosis
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
MX2011009751A (es) * 2009-03-16 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
US9610363B2 (en) 2009-04-16 2017-04-04 President And Fellows Of Harvard College Methods for inhibiting starvation of a cell
US20130288985A1 (en) * 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
US11879133B2 (en) * 2017-04-24 2024-01-23 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders

Similar Documents

Publication Publication Date Title
JP2016535034A5 (cg-RX-API-DMAC10.html)
JP2022141670A5 (cg-RX-API-DMAC10.html)
Liu et al. Gene therapy for ocular diseases
HRP20211024T4 (hr) Aav vektori za gensku terapiju mrežnice i cns-a
JP2017518271A5 (cg-RX-API-DMAC10.html)
JP2021503914A5 (cg-RX-API-DMAC10.html)
JP2019518427A5 (cg-RX-API-DMAC10.html)
HRP20251248T1 (hr) Liječenje amd-a upotrebom varijante aav2 s afliberceptom
JP2018510620A5 (cg-RX-API-DMAC10.html)
JP2020528734A5 (cg-RX-API-DMAC10.html)
JP2021511030A5 (cg-RX-API-DMAC10.html)
JP2017510296A5 (cg-RX-API-DMAC10.html)
WO2022221404A3 (en) Adeno-associated virus compositions having increased brain enrichment
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
HRP20201831T1 (hr) Optimizirani promoter rpe65 i kodirajuće sekvence
JP2018516869A5 (cg-RX-API-DMAC10.html)
JP7289306B2 (ja) 網膜障害を治療するための組成物及び方法
JP2022529782A (ja) シュタルガルト病（ａｂｃａ４）の遺伝子治療
JP2011511090A5 (cg-RX-API-DMAC10.html)
JP2021510301A5 (cg-RX-API-DMAC10.html)
Xia et al. Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies
CA3244412A1 (en) MODIFIED VAA CAPSID PROTEIN AND RELATED USES
JP2022533983A5 (cg-RX-API-DMAC10.html)
Ku et al. Retinal gene therapy: current progress and future prospects
JP2024105661A (ja) 眼疾患に対するａｄｅｎｏ随伴ウイルス連ウイルスベクター媒介遺伝子治療